Inovio Pharmaceuticals, Inc. (INO)
PHARMACEUTICAL PREPARATIONS
Inovio Pharmaceuticals, Inc. (INO) is listed on Nasdaq, where it has traded since December 8, 1998.
- Listed On
- Nasdaq
- Listed Since
- December 8, 1998
- Employees
- 112
- Market Cap
- $134M
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 101 institutions reported holding INO, with 32.8 million shares worth $36.1 million in aggregate. The largest reported holder was FMR, with 8.5 million shares worth $9.3 million. Of the 5 largest holders listed below, 4 added shares and 1 reduced its position during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 8,454,797 | $9M | Reduced 9.47% |
| Janus Henderson (Jupiter Topco) | 5,171,053 | $6M | Added 56.3% |
| Vanguard | 4,161,566 | $5M | Added 25.22% |
| Boxer Capital Management | 2,844,994 | $3M | Added 20.04% |
| Adar1 Capital Management | 2,143,910 | $2M | Added 45.83% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is INO?
Inovio Pharmaceuticals, Inc. (INO) is listed on Nasdaq, where it has traded since December 8, 1998.
Who are the largest institutional holders of INO?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of INO were FMR, Janus Henderson (Jupiter Topco) and Vanguard.
How many institutions own INO?
101 institutions reported a position in INO for the quarter ended June 30, 2026, worth $36.1 million in total.
Did institutions buy or sell INO last quarter?
Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter. Every reported holder and its change is on the SentiSense ownership page for INO.
Every reported institutional holder, plus insider and congressional trades in INO, on SentiSense.